Māori-founded Rua Bioscience Ltd (NZE: RUA) says it has signed the firm’s largest export agreement to date with a major British medicinal cannabis clinic and distribution business.
The deal, announced on Jul. 13, covers the supply of New Zealand-grown medical cannabis flower and generates expected revenue of more than US$5.8 million over the initial two-year term. The unnamed partner, whose identity will be revealed later, is granting Rua immediate access to an established network of clinics, pharmacies and prescribers.
The news comes as the UK medical cannabis sector expands rapidly. Imports more than doubled to over 30 tonnes in 2025 while the market reached an estimated £226 million valuation that year, up 103 per cent year-over-year. Patient numbers have climbed above 140,000, according to London market researcher Prohibition Partners, yet the sector still depends almost entirely on imports.
Relative to Rua’s US$7 million market capitalisation, this US$5.8 million contract is transformative in scale, but it also magnifies the risk of execution failure.
Read more: Rua Bioscience exports cannabis clones from New Zealand to Canada
Financial boost for struggling producer
Rua has been continually reporting losses. The company holds limited cash and depends heavily on repeated capital raises and shareholder support to sustain operations. This UK contract provides a notable revenue injection that may ease immediate cash pressures and reduce short-term reliance on equity funding.
However, questions remain over whether the company can fulfill this agreement effectively and convert this deal into sustained profitability amid its history of cash burn. Share price volatility and past dilution add to investor concerns about long-term stability.
Rua Bioscience remains the only medical cannabis company listed on New Zealand’s national stock exchange. Investors may see some appeal in its unique listed exposure to the sector and potential revenue growth from New Zealand genetics, but risks around ongoing losses and the need for further capital may lessen that interest.
“No one said this was an easy industry but we are making deliberate, intentional progress,” said CEO Paul Naske on social media this week.
Read more: New Zealand’s Rua Bioscience provides unique cannabis genetics to Ontario’s Apollo Green
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
